PET/CT Imaging in Oncology: Innovations, Challenges, and Opportunities

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nuclear Medicine & Radiology".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 601

Special Issue Editors


E-Mail Website
Guest Editor
Nuclear Medicine Unit, E.O. Ospedali Galliera, Genoa, Italy
Interests: nuclear medicine; radioactive iodine therapy; differentiated thyroid cancer; PET/CT; pediatrics; neuroblastoma; 131I MIBG therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Nuclear Medicine Unit, E.O. Ospedali Galliera, Genoa, Italy
Interests: nuclear medicine; radioisotope therapy; PET/CT; hematology; plaque imaging; image segmentation; texture analysis; radiomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

PET/CT has been the fastest-growing image modality in recent decades. This growth has been bolstered, on one hand, by the approval of new radiotracers, which have been instrumental in addressing the known limitations of FDG. On the other hand, the constant research of new possible indications of FDG-PET has led to the implementation of this tracer in many new clinical settings (e.g., image-guided surgery). Finally, advanced image analysis (including, but not limited to, radiomics, machine learning, automatic target segmentation, computer vision, augmented reality, etc.) has given new value to the acquired data and possesses the potential to increase the volume of information that imaging specialists and clinicians are able to extract from images. These aspects represent the pillars that will support the further growth of nuclear medicine. This Special Issue aims to include a selection of high-quality papers on the clinical and research applications of FDG and non-FDG tracers. Moreover, it will include scientific reports of advanced methods of image analysis, with a particular focus on image-based dosimetry and quantification, automatic segmentation, tumor burden calculation, computer-assisted diagnosis, and machine learning methods. The overall objective of this Special Issue is to provide an overview of the future directions of molecular imaging research, and, more in general, of innovative image analysis techniques.

I am pleased to invite you to contribute to this Special Issue, entitled "PET/CT Imaging in Oncology: Innovations, Challenges, and Opportunities". This is a new volume of a Special Issue in which we published 16 papers in its first incarnation. For further details, please visit: https://www.mdpi.com/journal/jcm/special_issues/PET_CT_Imaging

Dr. Arnoldo Piccardo
Dr. Francesco Fiz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET/CT
  • tumor
  • diagnosis
  • molecular imaging
  • machine learning
  • deep learning
  • Artificial Intelligence

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

16 pages, 1298 KiB  
Systematic Review
The Clinical Role of CXCR4-Targeted PET on Lymphoproliferative Disorders: A Systematic Review
by Maryam Zamanian, Domenico Albano, Giorgio Treglia, Alessio Rizzo and Iraj Abedi
J. Clin. Med. 2024, 13(10), 2945; https://doi.org/10.3390/jcm13102945 - 16 May 2024
Viewed by 398
Abstract
Background/Objectives: We conducted a comprehensive investigation to explore the pathological expression of the CXCR4 receptor in lymphoproliferative disorders (LPDs) using [68Ga]Ga-Pentixafor PET/CT or PET/MRI technology. The PICO question was as follows: What is the diagnostic role (outcome) of [68Ga]Ga-Pentixafor [...] Read more.
Background/Objectives: We conducted a comprehensive investigation to explore the pathological expression of the CXCR4 receptor in lymphoproliferative disorders (LPDs) using [68Ga]Ga-Pentixafor PET/CT or PET/MRI technology. The PICO question was as follows: What is the diagnostic role (outcome) of [68Ga]Ga-Pentixafor PET (intervention) in patients with LPDs (problem/population)? Methods: The study was written based on the reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines, and it was registered on the prospective register of systematic reviews (PROSPERO) website (CRD42024506866). A comprehensive computer literature search of Scopus, MEDLINE, Scholar, and Embase databases was conducted, including articles indexed up to February 2024. To the methodological evaluation of the studies used the quality assessment of diagnosis accuracy studies-2 (QUADAS-2) tool. Results: Of the 8380 records discovered, 23 were suitable for systematic review. Fifteen studies (on 571 LPD patients) focused on diagnosis and staging, and eight trials (194 LPD patients) assessed treatment response. Conclusions: The main conclusions that can be inferred from the published studies are as follows: (a) [68Ga]Ga-Pentixafor PET may have excellent diagnostic performance in the study of several LPDs; (b) [68Ga]Ga-Pentixafor PET may be superior to [18F]FDG or complementary in some LPDs variants and settings; (c) multiple myeloma seems to have a high uptake of [68Ga]Ga-Pentixafor. Overall, this technique is probably suitable for imaging, staging, and follow-up on patients with LPD. Due to limited data, further studies are warranted to confirm the promising role of [68Ga]Ga-Pantixafor in this context. Full article
Show Figures

Figure 1

Back to TopTop